<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2306222250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Truvelog
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        INSULIN ASPART
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        141.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Sanofi aventis Deutschland GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Sanofi aventis Deutschland GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2218]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Sanofi Arabia Trading Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SANOFI AVENTIS GROUPE
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10AB05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Truvelog is a modern insulin (insulin analogue) with a rapid-acting effect. Modern insulin products are improved versions of human insulin.<br />Truvelog is used to reduce the high blood sugar level in adults, adolescents and children aged 1 year and above with diabetes mellitus (diabetes). Diabetes is a disease where your body does not produce enough insulin to control the level of your blood sugar. Treatment with Insulin aspart Sanofi helps to prevent complications from your diabetes.<br />Truvelog will start to lower your blood sugar 10&ndash;20 minutes after you inject it, a maximum effect occurs between 1 and 3 hours after the injection and the effect lasts for 3&ndash;5 hours. Due to this short action Truvelog should normally be taken in combination with intermediate-acting or long-acting insulin preparations.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Truvelog<br />&bull; If you are allergic to insulin aspart, or any of the other ingredients of this medicine (listed in section 6).<br />&bull; If you suspect hypoglycaemia (low blood sugar) is starting (see &ldquo;Summary of serious and very common side effects&rdquo; in section 4)<br />&bull; If pre-filled pen is dropped, damaged or crushed.<br />&bull; If it has not been stored correctly or been frozen (see &ldquo;How to store Truvelog&rdquo; in section 5).<br />&bull; If the insulin does not appear clear and colourless.<br />If any of these applies, do not use Truvelog. Talk with your doctor, nurse or pharmacist for advice.<br />Before using Truvelog<br />&bull; Check the label to make sure it is the right type of insulin.<br />&bull; Always use a new needle for each injection to prevent contamination.<br />&bull; Needles and pre-filled pen must not be shared.<br />&bull; Truvelog is only suitable for injecting under the skin. Speak to your doctor if you need to inject your insulin by another method.<br />Warnings and precautions<br />Record the brand name (&ldquo;Truvelog&rdquo;) and Lot number (included on the outer cartons and labels of each pre-filled pen) of the product you are using and provide this information when reporting any side effects.<br />Some conditions and activities can affect your need for insulin. Consult your doctor:<br />&bull; If you have trouble with your kidneys or liver, or with your adrenal, pituitary or thyroid glands.<br />&bull; If you exercise more than usual or if you want to change your usual diet, as this may affect your blood sugar level.<br />&bull; If you are ill, carry on taking your insulin and consult your doctor.<br />&bull; If you are going abroad, travelling over time zones may affect your insulin needs and the timing of your injections.<br />Children and adolescents<br />Do not give this medicine to children below 1 year of age since no clinical studies have been carried out in children below the age of 1 year.<br />Other medicines and Truvelog<br />Tell your doctor, nurse or pharmacist if you are taking, have recently taken or might take any other medicines.<br />Some medicines affect your blood sugar level and this may mean that your insulin dose has to change. Listed below are the most common medicines which may affect your insulin treatment.<br />Your blood sugar level may fall (hypoglycaemia) if you take:<br />&bull; Other medicines for the treatment of diabetes<br />&bull; Monoamine oxidase inhibitors (MAOI) (used to treat depression)<br />&bull; Beta&ndash;blockers (used to treat high blood pressure)<br />&bull; Angiotensin converting enzyme (ACE) inhibitors (used to treat certain heart conditions or high blood pressure)<br />&bull; Salicylates (used to relieve pain and lower fever)<br />&bull; Anabolic steroids (such as testosterone)<br />&bull; Sulphonamides (used to treat infections).<br />Your blood sugar level may rise (hyperglycaemia) if you take:<br />&bull; Oral contraceptives (birth control pills)<br />&bull; Thiazides (used to treat high blood pressure or excessive fluid retention)<br />&bull; Glucocorticoids (such as &lsquo;cortisone&rsquo; used to treat inflammation)<br />&bull; Thyroid hormones (used to treat thyroid gland disorders)<br />&bull; Sympathomimetics (such as epinephrine [adrenaline], or salbutamol, terbutaline used to treat asthma)<br />&bull; Growth hormone (medicine for stimulation of skeletal and somatic growth and pronounced influence on the body&rsquo;s metabolic processes)<br />&bull; Danazol (medicine acting on ovulation).<br />Octreotide and lanreotide (used for treatment of acromegaly, a rare hormonal disorder that usually occurs in middle&ndash;aged adults, caused by the pituitary gland producing excess growth hormone) may either increase or decrease your blood sugar level.<br />Beta&ndash;blockers (used to treat high blood pressure) may weaken or suppress entirely the first warning symptoms which help you to recognise low blood sugar.<br />Pioglitazone (tablets used for the treatment of type 2 diabetes)<br />Some patients with long&ndash;standing type 2 diabetes and heart disease or previous stroke who were treated with pioglitazone and insulin experienced the development of heart failure. Inform your doctor as soon as possible if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema).<br />If you have taken any of the medicines listed here, tell your doctor, nurse or pharmacist.<br />Truvelog and alcohol<br />If you drink alcohol, your need for insulin may change as your blood sugar level may either rise or fall. Careful monitoring is recommended.<br />Pregnancy and breast-feeding<br />If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Truvelog can be used during pregnancy. Your insulin dose may need to be changed during pregnancy and after delivery. Careful control of your diabetes, particularly prevention of hypoglycaemia, is important for the health of your baby.<br />There are no restrictions on treatment with Truvelog during breast-feeding.<br />Ask your doctor, nurse or pharmacist for advice before taking this medicine while pregnant or breast-feeding.<br />Driving and using machines<br />Please ask your doctor whether you can drive a car or use a machine:<br />&bull; If you have frequent hypoglycaemia.<br />&bull; If you find it hard to recognise hypoglycaemia.<br />If your blood sugar is low or high, your concentration and ability to react might be affected and therefore also your ability to drive or use a machine. Bear in mind that you could endanger yourself or others.<br />Truvelog has a rapid onset of effect therefore if hypoglycaemia occurs, you may experience it earlier after an injection when compared to soluble human insulin.<br />Truvelog contains sodium<br />This medicine contains less than 1 mmol (23 mg) sodium per dose, that to say essentially &ldquo;sodium- free&rdquo;.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dose and when to use your insulin<br />Always use your insulin and adjust your dose exactly as your doctor has told you. Check with your doctor, nurse or pharmacist if you are not sure.<br />Truvelog is generally used immediately before a meal. Eat a meal or snack within<br />10 minutes of the injection to avoid low blood sugar. When necessary, Truvelog can be given soon after a meal (see &ldquo;How and where to inject below for information&rdquo;).<br />Do not change your insulin unless your doctor tells you to. If your doctor has switched you from one type or brand of insulin to another, your dose may have to be adjusted by your doctor.<br />Use in children and adolescents<br />Truvelog can be used in adolescents and children aged 1 year and above instead of soluble human insulin when a rapid onset of effect is preferred. For example, when it is difficult to dose the child in relation to meals.<br />Use in special patient groups<br />If you have reduced kidney or liver function, or if you are above 65 years of age, you need to check your blood sugar more regularly and discuss changes in your insulin dose with your doctor.<br />How and where to inject<br />Truvelog is for injection under the skin (subcutaneously). You must never inject yourself directly into a vein (intravenously) or muscle (intramuscularly). Truvelog is only suitable for injecting under the skin. Speak to your doctor if you need to inject your insulin by another method.<br />With each injection, change the injection site within the particular area of skin that you use. This may reduce the risk of developing lumps or skin pitting (see section 4 &ldquo;Possible side effects&rdquo;). The best places to give yourself an injection are: the front of your waist (abdomen), the upper arm or the front of your thighs. The insulin will work more quickly if you inject into the front of your waist (abdomen). You should always measure your blood sugar regularly.<br />How to handle Truvelog SoloStar pre-filled pen<br />Truvelog SoloStar is a pre-filled disposable pen containing insulin aspart. Each SoloStar pen delivers 1-80 units in increments of 1 unit.<br />Read carefully the instructions for use included in this package leaflet. You must use the pen as described in the Instructions for Use.<br />Always ensure you use the correct pen before you inject your insulin.<br />If you use more insulin than you should<br />If you use too much insulin your blood sugar gets too low (hypoglycaemia) (see &ldquo;Summary of serious and very common side effects&rdquo; in section 4).<br />If you forget to use your insulin<br />If you forget to use your insulin your blood sugar may get too high (hyperglycaemia) (see &ldquo;Effects from diabetes&rdquo; in section 4).<br />If you stop using your insulin<br />Do not stop using your insulin without speaking with a doctor, who will tell you what needs to be done. This could lead to very high blood sugar (severe hyperglycaemia) and ketoacidosis (see &ldquo;Effects from diabetes&rdquo; in section 4).<br />If you have any further questions on the use of this medicine, ask your doctor, nurse or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />Summary of serious and very common side effects<br />Low blood sugar (hypoglycaemia) is a very common side effect. It may affect more than 1 in 10 people.<br />Low blood sugar may occur if you:<br />&bull; Inject too much insulin.<br />&bull; Eat too little or miss a meal.<br />&bull; Exercise more than usual.<br />&bull; Drink alcohol (see &quot;Insulin aspart Sanofi with alcohol&rdquo; in section 2).<br />Signs of low blood sugar:<br />Cold sweat; cool pale skin; headache; rapid heartbeat; feeling sick; feeling very hungry; temporary changes in vision; drowsiness; unusual tiredness and weakness; nervousness or tremor; feeling anxious; feeling confused; difficulty in concentrating.<br />Severe low blood sugar can lead to unconsciousness. If prolonged severe low blood sugar is not treated, it can cause brain damage (temporary or permanent) and even death. You may recover more quickly from unconsciousness with an injection of the hormone glucagon by someone who knows how to use it. If you are given glucagon you will need glucose or a sugar snack as soon as you are conscious. If you do not respond to glucagon treatment, you will have to be treated in a hospital.<br />What to do if you experience low blood sugar:<br />&bull; If you experience low blood sugar, eat glucose tablets or another high sugar snack (e.g. sweets, biscuits, fruit juice). Measure your blood sugar if possible and rest. Always carry glucose tablets or high sugar snacks with you, just in case.<br />&bull; When symptoms of low blood sugar have disappeared or when blood sugar level is stabilised, continue insulin treatment as usual.<br />&bull; If you have such a low blood sugar that it makes you pass out, if you have had need for injection of glucagon, or if you have experienced many incidents of low blood sugar, talk with a doctor. The amount or timing of insulin, food or exercise may need to be adjusted.<br />Tell relevant people that you have diabetes and what the consequences may be, including the risk of passing out (become unconscious) due to low blood sugar. Let them know that if you pass out, they must turn you on your side and get medical help straight away. They must not give you any food or drink due to risk of suffocation.<br />Serious allergic reactions to Insulin aspart Sanofi or one of its ingredients (called a systemic allergic reaction) is a very rare side effect but can potentially be life threatening. It may affect up to 1 in 10,000 people.<br />Seek medical advice immediately:<br />&bull; If signs of allergy spread to other parts of your body.<br />&bull; If you suddenly feel unwell, and you: start sweating; start being sick (vomiting); have difficulty in breathing; have a rapid heartbeat; feel dizzy.<br />If you notice any of these signs, seek medical advice immediately.<br />Other side effects<br />Uncommon (may affect up to 1 in 100 people)<br />Signs of allergy: Local allergic reactions (pain, redness, hives, inflammation, bruising, swelling and itching) at the injection site may occur. These usually disappear after a few weeks of using your insulin. If they do not disappear, or if they spread throughout your body, talk to your doctor immediately (see also &ldquo;Serious allergic reactions above).<br />Vision problems: When you first start your insulin treatment, it may disturb your vision, but the disturbance is usually temporary.<br />Changes at the injection site (lipodystrophy): The fatty tissue under the skin at the injection site may shrink (lipoatrophy) or thicken (lipohypertrophy). Changing the site with each injection reduces the<br />risk of developing such skin changes. If you notice your skin pitting or thickening at the injection site, tell your doctor or nurse. These reactions can become more severe, or they may change the absorption of your insulin, if you inject in such a site.<br />Swollen joints: When you start using insulin, water retention may cause swelling around your ankles and other joints. Normally this soon disappears. If not, talk to your doctor.<br />Diabetic retinopathy (an eye disease related to diabetes which can lead to loss of vision): If you have diabetic retinopathy and your blood sugar level improves very fast, the retinopathy may get worse. Ask your doctor about this.<br />Rare (may affect up to 1 in 1,000 people)<br />Painful neuropathy (pain due to nerve damage): If your blood sugar level improves very fast, you may get nerve related pain, this is called acute painful neuropathy and is usually transient.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system. By reporting side effects you can help provide more information on the safety of this medicine.<br />Effects from diabetes<br />High blood sugar (hyperglycaemia)<br />High blood sugar may occur if you:<br />&bull; Have not injected enough insulin.<br />&bull; Forget to inject your insulin or stop using insulin.<br />&bull; Repeatedly inject less insulin than you need.<br />&bull; Get an infection and/or a fever.<br />&bull; Eat more than usual.<br />&bull; Exercise less than usual.<br />Warning signs of high blood sugar:<br />The warning signs appear gradually. They include: increased urination; feeling thirsty; losing your appetite; feeling sick (nausea or vomiting); feeling drowsy or tired; flushed; dry skin; dry mouth and a fruity (acetone) smell of the breath.<br />What to do if you experience high blood sugar<br />&bull; If you get any of the above signs: test your blood sugar level, test your urine for ketones if you can, then seek medical advice immediately.<br />&bull; These may be signs of a very serious condition called diabetic ketoacidosis (build-up of acid in the blood because the body is breaking down fat instead of sugar). If you do not treat it, this could lead to diabetic coma and eventually death.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the label and carton. The expiry date refers to the last day of that month.<br />Before the first use store your Truvelog in a refrigerator (2&deg;C &ndash; 8&deg;C). Do not freeze. Keep the pre-filled pen in the outer carton in order to protect from light.<br />Keep your Truvelog pre-filled pen in use at room temperature (below 30&deg;C) for a maximum of 4 weeks. Do not keep the pre-filled pen that you are using in the fridge. The pre-filled pen should not be stored with the needle attached. Always keep the cap on the pre-filled pen when you are not using it in order to protect from light.<br />Do not use Truvelog pre-filled pen if the solution is coloured or it has solid pieces in it. You must use it only if it looks like water. Check this each time you inject yourself.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is insulin aspart. One ml of the solution contains 100 units (equivalent to<br />3.5 mg) of insulin aspart. Each pre-filled pen (SoloStar) contains 3 ml of solution for injection, equivalent to 300 units of insulin aspart. Each pre-filled pen (SoloStar) delivers 1-80 units in steps of 1 unit.<br />&bull; The other ingredients are: phenol, metacresol, zinc chloride, polysorbate 20, sodium chloride, hydrochloric acid/sodium hydroxide and water for injections. Sodium hydroxide or hydrochloric acid may have been used to adjust the acidity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Truvelog solution for injection is a clear, colourless, aqueous solution. Each pre-filled pen (SoloStar) contains 3 ml.
Only use needles that are compatible for use with Truvelog (e.g. needles from BD, Ypsomed, Artsana or Owen Mumford).
Truvelog in pre-filled pen (SoloStar) comes in a pack of 5 pre-filled pens.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder:<br />sanofi-aventis groupe, 54, rue La Bo&eacute;tie, F - 75008 Paris, France<br />Manufacturer:<br />Sanofi-Aventis Deutschland GmbH, D-65926 Frankfurt am Main, Germany.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Dec 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تروفيلوغ هو أنسولين حديث (نظير الأنسولين) له تأثير سريع المفعول. منتجات الأنسولين الحديثة هي نسخ محسنة من الأنسولين البشري.</p><p dir="RTL">يُستخدم تروفيلوغ لخفض مستوى السكر المرتفع في الدم لدى البالغين والمراهقين والأطفال الذين تتراوح أعمارهم بين سنة وما فوق المصابين بداء السكري (مرض السكري). مرض السكري هو مرض تقلّ معه قدرة &nbsp;جسمك على انتاج ما يكفي من الأنسولين للتحكم في مستوى السكر في الدم لديك. يساعد العلاج باستخدام الأنسولين أسبارت لسانوفي على منع حدوث مضاعفات مرض السكري.</p><p>يبدأ تروفيلوغ في خفض نسبة السكر في الدم لديك بعد 10-20 دقيقة من حقنك به، ويصل تأثيره إلى الذروة بين 1 و 3 ساعات بعد الحقن ويستمر التأثير لمدة 3-5 ساعات. ونظرًا لقصر مدة تأثيره، يجب استخدام تروفيلوغ مع مستحضرات الأنسولين متوسطة المفعول أو طويلة المفعول.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم تروفيلوغ </strong></p><p dir="RTL">&bull; إذا كان لديك حساسية نحو الأنسولين أسبارت، أو أيّ من المكونات الأخرى لهذا الدواء (المدرجة في الفقرة 6).</p><p dir="RTL">&bull; إذا كنت تشتبه في بدء تعرّضك لنقص سكر الدم (انخفاض سكر الدم) (انظر &quot;ملخص الأعراض الجانبية<br />&nbsp; الخطيرة والشائعة جدًا&quot; في القسم 4)</p><p dir="RTL">&bull; في حالة سقوط القلم المسبق التعبئة أو تلفه أو كسره.</p><p dir="RTL">&bull; إذا لم يتم تخزينه بشكل صحيح أو تم تجميده (راجع &quot;كيفية تخزين تروفيلوغ&quot; في الفقرة 5).<br />&nbsp;</p><p dir="RTL">&bull; إذا لم يبدو محلول الأنسولين بشكلٍ صافٍ وعديم اللون.</p><p dir="RTL">إذا انطبق عليك أيّ من هذه الحالات، فلا تستخدم تروفيلوغ. تحدث مع طبيبك أو ممرضتك أو الصيدلي للحصول على المشورة.</p><p dir="RTL"><strong>قبل استخدام تروفيلوغ </strong></p><p dir="RTL">&bull; تحقق من الملصق للتأكد من أنه النوع الصحيح من الأنسولين.</p><p dir="RTL">&bull; استخدم دائمًا إبرة جديدة لكل جرعة حقن تجنّبًا لحدوث التلوث.</p><p dir="RTL">&bull; يجب عدم مشاركة الإبر والقلم مُسبق التعبئة مع أي أحد آخر.</p><p dir="RTL">&bull; تروفيلوغ مناسب للحقن تحت الجلد فقط. تحدث إلى طبيبك إذا كنت بحاجة إلى حقن الأنسولين بطريقة أخرى.<br />&nbsp;</p><p dir="RTL"><strong>المحاذير والإحتياطات</strong></p><p dir="RTL">سجّل الاسم التجاري (&quot;تروفيلوغ&quot;) ورقم الدفعة (المُدرج في علبة الكرتون الخارجية وملصقات كل قلم مسبق التعبئة) للمنتج الذي تستخدمه وقدم هذه المعلومات عند الإبلاغ عن أي أعراض جانبية.<br />&nbsp;</p><p dir="RTL">يمكن أن تؤثر بعض الحالات والأنشطة على حاجتك للأنسولين. استشر طبيبك إذا كنت:</p><p dir="RTL">&bull; تعاني من مشاكل في الكلى أو الكبد أو في الغدة الكظرية أو الغدة النخامية أو الغدة الدرقية.</p><p dir="RTL">&bull; تمارس الرياضة أكثر من المعتاد أو إذا كنت ترغب في تغيير نظامك الغذائي المعتاد، فقد يؤثر ذلك<br />&nbsp; على مستوى السكر في الدم لديك.</p><p dir="RTL">&bull; مريضًا، استمر في تناول الأنسولين واستشر طبيبك.</p><p dir="RTL">&bull; مسافرًا إلى الخارج، فقد يؤثر السفر عبر مناطق زمنية مختلفة على احتياجاتك من الأنسولين وتوقيت<br />&nbsp;&nbsp;الحقن.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا تعطِ هذا الدواء للأطفال الذين تقل أعمارهم عن سنة واحدة حيث لم يتم إجراء دراسات سريرية على هذه الفئة العمرية من الأطفال.<br />&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وتروفيلوغ</strong></p><p dir="RTL">أخبر طبيبك أو ممرضتك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">تؤثر بعض الأدوية على مستوى السكر في الدم، وهذا قد يعني أن جرعة الأنسولين التي تستخدمها يجب أن تتغير. الأدوية المدرجة أدناه هي الأدوية الأكثر شيوعًا التي قد تؤثر على علاج الأنسولين الخاص بك.</p><p dir="RTL"><u>قد ينخفض مستوى السكر في الدم لديك (نقص سكر الدم) إذا كنت تتناول:</u></p><p dir="RTL">&bull; أدوية أخرى لعلاج مرض السكري</p><p dir="RTL">&bull; مثبطات الأوكسيديز أحادي الأمين (MAOI) (تستخدم لعلاج الاكتئاب)</p><p dir="RTL">&bull; حاصرات بيتا (تستخدم لعلاج ارتفاع ضغط الدم)</p><p dir="RTL">&bull; مثبطات الإنزيم المحول للأنجيوتِنسين (تستخدم لعلاج بعض أمراض القلب أو ارتفاع ضغط الدم)</p><p dir="RTL">&bull; الساليسيلات (تستخدم لتسكين الألم وخفض الحمى)</p><p dir="RTL">&bull; الستيرويدات الابتنائية (مثل التستوستيرون)</p><p dir="RTL">&bull; السلفوناميدات (المستعملة لعلاج الالتهابات)<br />&nbsp;</p><p dir="RTL"><u>قد يرتفع مستوى السكر في الدم لديك (فرط سكر الدم) إذا كنت تتناول:</u></p><p dir="RTL">&bull; موانع الحمل الفموية (حبوب منع الحمل)</p><p dir="RTL">&bull; الثيازيدات (تستخدم لعلاج ارتفاع ضغط الدم أو احتباس السوائل المفرط)</p><p dir="RTL">&bull; الهرمونات القشرية السكرية (مثل &quot;الكورتيزون&quot; المستخدم لعلاج الالتهاب)</p><p dir="RTL">&bull; هرمونات الغدة الدرقية (المستخدمة لعلاج اضطرابات الغدة الدرقية)</p><p dir="RTL">&bull; محاكيات الودي (مثل الإبينفرين [الأدرينالين]، أو السالبوتامول، أو تيربوتالين المستخدم لعلاج الربو)</p><p dir="RTL">&bull; هرمون النمو (دواء لتحفيز النمو الهيكلي والجسدي وله تأثير واضح على عمليات التمثيل الغذائي في<br />&nbsp; الجسم)</p><p dir="RTL">&bull; دانازول (دواء يؤثر على الإباضة).<br />&nbsp;</p><p dir="RTL">يؤدي استخدام أوكتريوتيد ولانريوتيد (يستخدمان لعلاج ضخامة الأطراف، وهو اضطراب هرموني نادر يحدث عادةً لدى البالغين في منتصف العمر، بسبب فرط إفراز الغدة النخامية لهرمون النمو) إلى زيادة أو خفض مستوى السكر في الدم.</p><p dir="RTL">قد تضعف حاصرات بيتا (المستخدمة لعلاج ارتفاع ضغط الدم) أو تكبح تمامًا الأعراض التحذيرية الأولى التي تساعدك على التعرف على انخفاض نسبة السكر في الدم.</p><p dir="RTL"><u>بيوغليتازون (أقراص تستخدم لعلاج داء السكري من النوع الثاني)</u></p><p dir="RTL">تعرّض بعض المرضى الذين يعانون من مرض السكري من النوع 2 وأمراض القلب طويلة الأمد أو السكتة الدماغية السابقة والذين عولجوا ببيوغليتازون والأنسولين للإصابة بقصور في القلب. أخبر طبيبك في أقرب وقت ممكن إذا كنت تعاني من علامات قصور القلب مثل ضيق غير عادي في التنفس أو زيادة سريعة في الوزن أو تورم موضعي (وذمة).</p><p dir="RTL">إذا تناولت أيًا من الأدوية المذكورة هنا، أخبر طبيبك أو ممرضتك أو الصيدلي.</p><p><br /><strong>تروفيلوغ والكحول</strong><br />إذا كنت تشرب الكحول، فقد تتغير حاجتك إلى الأنسولين حيث قد يرتفع مستوى السكر في الدم أو ينخفض.<br />&nbsp;</p><p dir="RTL">يُنصح بالمراقبة الدقيقة.<br />&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنتِ حاملاً، أو تعتقدين أنكِ حامل أو تخططين لإنجاب طفل، اسألي طبيبك للحصول على المشورة قبل تناول هذا الدواء. يمكن استخدام تروفيلوغ أثناء الحمل. قد تحتاج جرعة الأنسولين الخاصة بكِ إلى التغيير أثناء الحمل وبعد الولادة. إن التحكم الدقيق في مرض السكري لديك، وخاصة الوقاية من نقص السكر في الدم، أمر مهم لصحة طفلك.</p><p dir="RTL">لا توجد قيود على استخدام تروفيلوغ أثناء الرضاعة الطبيعية.</p><p dir="RTL">اسألي طبيبك أو الممرضة أو الصيدلي للحصول على المشورة قبل تناول هذا الدواء أثناء الحمل أو الرضاعة.</p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">يُرجى سؤال طبيبك عما إذا كان بإمكانك قيادة السيارة أو استخدام الآلات إذا:</p><p dir="RTL">&bull; كنت تعاني من نقص سكر الدم بشكل متكرر.</p><p dir="RTL">&bull; وجدت صعوبة في تحديد حالة نقص سكر الدم لديك.</p><p dir="RTL">قد يتأثر تركيزك وقدرتك على التفاعل إذا ارتفع أو انخفض مستوى السكر لديك في الدم، وبالتالي قد تتأثر قدرتك على القيادة أو استخدام الآلات أيضًا. ضع في اعتبارك أنك قد تُعرّض نفسك أو الآخرين للخطر.</p><p dir="RTL">يبدأ تأثير تروفيلوغ سريعًا، لذلك إذا حدث نقص سكر الدم، فقد تواجهه مبكرًا بعد الحقن عند مقارنته بالأنسولين البشري القابل للذوبان.</p><p dir="RTL"><strong>يحتوي تروفيلوغ على الصوديوم</strong><br />يحتوي هذا الدواء على أقل من 1 مليمول (23 مجم) صوديوم في كل جرعة، وهذا يعني أنّه &quot;خال من الصوديوم&quot; بشكل أساسي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الجرعة وأوقات استخدام الأنسولين</strong></p><p dir="RTL">استخدم الأنسولين دائمًا واضبط جرعتك تمامًا حسب إرشادات طبيبك. استشر طبيبك أو ممرضتك أو الصيدلي إذا لم تكن متأكدًا.</p><p dir="RTL">يُستخدم تروفيلوغ بشكل عام قبل الوجبة مباشرة. تناول وجبة أو وجبة خفيفة في غضون 10 دقائق من الحقن لتجنب انخفاض مستوى السكر في الدم لديك. ويمكن إعطاء تروفيلوغ بعد الوجبة مباشرة عند الضرورة (انظر &quot;كيفية وموضع الحقن&quot; أدناه للحصول على معلومات).</p><p dir="RTL">لا تُغيّر الأنسولين إلا إذا أخبرك طبيبك بذلك. إذا قام طبيبك بتحويلك من نوع أو من علامة تجارية من الأنسولين إلى نوع آخر، فقد يتعين على طبيبك تعديل جرعتك.</p><p dir="RTL"><strong>استخدامه في الأطفال والمراهقين</strong></p><p dir="RTL">يمكن استخدام تروفيلوغ لدى المراهقين والأطفال الذين تتراوح أعمارهم بين سنة واحدة وما فوق بدلاً من الأنسولين البشري القابل للذوبان في الحالات التي تتطلب ظهور التأثير السريع للأنسولين. على سبيل المثال، عند مواجهة صعوبة في إعطاء الجرعة المرتبطة بالوجبة للطفل.<br />&nbsp;</p><p dir="RTL"><strong>استخدامه في فئات معيّنة من المرضى</strong></p><p dir="RTL">إذا كنت تعاني من قصور في وظائف الكلى أو الكبد، أو إذا كان عمرك يزيد عن 65 عامًا، فأنت بحاجة إلى فحص مستوى السكر في الدم بانتظام ومناقشة التغييرات في جرعة الأنسولين مع طبيبك.<br />&nbsp;</p><p dir="RTL"><strong>كيفية وموضع الحقن </strong></p><p dir="RTL">تروفيلوغ مُعدّ للحقن تحت الجلد. يجب ألا تحقن نفسك مباشرة في الوريد أو العضل. تروفيلوغ مناسب للحقن تحت الجلد فقط. تحدث إلى طبيبك إذا كنت بحاجة إلى حقن الأنسولين بطريقة أخرى.</p><p dir="RTL">قم بتغيير موضع الحقن في كل جرعة حقن ضمن المنطقة من الجلد التي تستخدمها. قد يقلل هذا من خطر حدوث تكتل أو تنقر في الجلد (انظر القسم 4 &quot;الأعراض الجانبية المحتملة&quot;). أفضل الأماكن للحقن هي: الجزء الأمامي من الخصر (منطقة البطن) أو الجزء العلوي من الذراع (العضد) أو الجزء الأمامي من الفخذين. سيعمل الأنسولين بسرعة أكبر إذا حقنته في الجزء الأمامي من خصرك (البطن). يجب عليك دائمًا قياس مستوى السكر في الدم بانتظام.</p><p dir="RTL"><strong>كيفية التعامل مع قلم تروفيلوغ سولوستار مسبق التعبئة </strong><br />تروفيلوغ سولوستار عبارة عن قلم يمكن التخلص منه، مسبق التعبئة يحتوي على الأنسولين أسبارت. يُتيح&nbsp; كل قلم سولوستار جرعات تتراوح من 1 &ndash; 80 وحدة للمرة الواحدة بزيادات مكونة من وحدة واحدة.</p><p dir="RTL">اقرأ بعناية تعليمات الاستخدام الواردة في نشرة المعلومات هذه. يجب عليك استخدام القلم كما هو موضح في تعليمات الاستخدام.</p><p dir="RTL">تأكد دائمًا من استخدام القلم الصحيح قبل حقن الأنسولين.<br />&nbsp;</p><p dir="RTL"><strong>إذا كنت تستخدم أنسولين أكثر مما ينبغي</strong></p><p dir="RTL">إذا كنت تستخدم أكثر مما ينبغي من الأنسولين، سينخفض مستوى السكر في الدم بشكل كبير لديك (نقص سكر الدم) (انظر &quot;ملخص الأعراض الجانبية الخطيرة والشائعة جدًا&quot; في الفقرة 4).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت استخدام الأنسولين</strong></p><p dir="RTL">إذا نسيت استخدام الأنسولين، فقد يرتفع مستوى السكر في الدم بشكل كبير لديك (فرط السكر في الدم) (انظر &quot;الآثار المترتبة على مرض السكري&quot; في القسم 4).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن استخدام الأنسولين</strong></p><p dir="RTL">لا تتوقف عن استخدام الأنسولين دون التحدث مع الطبيب الذي سيخبرك بما يجب القيام به. يمكن أن يؤدي توقفك عن استخدامه إلى ارتفاع شديد في سكر الدم (فرط سكر الدم الشديد) والحماض الكيتوني (انظر &quot;الآثار المترتبة على مرض السكري&quot; في القسم 4).</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو ممرضتك أو الصيدلي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع جميع الأدوية، يمكن أن يسبب هذا الدواء أعراضًا جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL"><strong>ملخص الأعراض الجانبية الخطيرة والشائعة جدًا</strong><br />&nbsp;</p><p dir="RTL"><strong>يعتبر انخفاض مستوى السكر في الدم (نقص سكر الدم)</strong> من الأعراض الجانبية الشائعة جدًا. قد تظهر لدى أكثر من 1 من كل 10 أشخاص.</p><p dir="RTL"><u>قد يحدث انخفاض في مستوى السكر في الدم إذا:</u></p><p dir="RTL">&bull; حقنت أكثر مما ينبغي من الأنسولين.</p><p dir="RTL">&bull; تناولت القليل من الطعام أو فوّتّ إحدى الوجبات.</p><p dir="RTL">&bull; مارست التمارين الرياضية أكثر من المعتاد.</p><p dir="RTL">&bull; تناولت الكحول (انظر &quot;الأنسولين أسبارت لسانوفي مع الكحول&quot; في الفقرة 2).</p><p dir="RTL"><u>علامات انخفاض سكر الدم:</u></p><p dir="RTL">عرق بارد؛ جلد شاحب بارد؛ صداع الراس؛ تسارع ضربات القلب؛ الغثيان؛ الشعور بالجوع الشديد؛ تغييرات مؤقتة في الرؤية؛ النعاس؛ التعب والضعف غير العادي؛ العصبية أو الرعاش؛ الشعور بالقلق؛ الشعور بالارتباك؛ صعوبة في التركيز.</p><p dir="RTL">يمكن أن يؤدي الانخفاض الحاد في مستوى السكر في الدم إلى فقدان الوعي. إذا لم يتم علاج الانخفاض الشديد المُطوّل في مستوى السكر في الدم، فقد يتسبب ذلك في تلف الدماغ (مؤقت أو دائم) وحتى الموت. قد تتعافى من حالة فقدان الوعي بسرعة أكبر إذا ما تم حقنك بهرمون الغلوكاغون من قبل شخص يعرف كيفية استخدامه. إذا تم إعطاؤك الغلوكاغون، فستحتاج إلى تناول الجلوكوز أو وجبة خفيفة من السكر بمجرد استردادك لوعيك. إذا لم تستجب للعلاج بالغلوكاغون، فسيتعين عليك العلاج في المستشفى.</p><p dir="RTL"><u>ماذا تفعل إذا تعرّضت لانخفاض في مستوى السكر في الدم:</u></p><p dir="RTL">&bull; إذا تعرّضت لانخفاض نسبة السكر في الدم، فتناول أقراص الجلوكوز أو أي وجبة خفيفة أخرى غنية<br />&nbsp; بالسكر (مثل الحلويات والبسكويت وعصير الفاكهة). ثمّ قم بقياس نسبة السكر في الدم إن أمكن واسترح.<br />&nbsp; احمل معك دائمًا أقراص الجلوكوز أو الوجبات الخفيفة الغنية بالسكر تحسباً لذلك.<br />&nbsp;</p><p dir="RTL">&bull; عندما تختفي أعراض نقص السكر في الدم أو عندما يستقر مستوى السكر في الدم، استمر في العلاج<br />&nbsp;&nbsp; بالأنسولين كالمعتاد.<br />&bull; إذا كنت تعاني من انخفاض في مستوى السكر في الدم لدرجة تجعلك تفقد وعيك، أو إذا كنت بحاجة إلى<br />&nbsp; حقن الغلوكاغون، أو إذا عانيت من تكرار حالات انخفاض السكر في الدم، فتحدث إلى الطبيب. قد يلزم<br />&nbsp; تعديل كمية أو توقيت الأنسولين أو الطعام أو التمرين لديك.</p><p dir="RTL">ينبغي أن تخبر الأشخاص المعنيين من حولك أنك مصاب بمرض السكري وبالعواقب المترتبة على ذلك، بما في ذلك خطر فقدانك الوعي بسبب انخفاض مستوى السكر في الدم.كما ينبغي أن تخبرهم ما الذي يتوجب عليهم فعله عند فقدانك الوعي، إذ يجب عليهم أن يجعلوك تستلقي على جانبك وأن يسارعوا في الحصول على المساعدة الطبية على الفور. يجب عليهم تجنّب إعطاؤك أيّ طعام أو شراب بسبب خطر التعرّض للاختناق.</p><p dir="RTL"><strong>تعتبر ردود الفعل التحسسية الخطيرة</strong> تجاه الأنسولين أسبارت سانوفي أو أحد مكوناته (تسمى تفاعل الحساسية الجهازية) من الأعراض الجانبية النادرة جدًا ولكنها قد تكون مهددة للحياة. قد تظهر لدى ما يصل إلى 1 من كل 10000 شخص.</p><p dir="RTL">اطلب المشورة الطبية فورًا في الحالات التالية:</p><p dir="RTL">&bull; إذا انتشرت علامات الحساسية إلى أجزاء أخرى من الجسم.</p><p dir="RTL">&bull; إذا شعرت فجأة بتوعك، وبدأت في التعرق، وبالتقيؤ، ووجدت صعوبة في التنفس مع تسارع ضربات القلب،<br />&nbsp; والشعور بالدوار.</p><p dir="RTL">إذا لاحظت أيًا من هذه العلامات، فاطلب المشورة الطبية على الفور.<br />&nbsp;</p><p dir="RTL"><strong>أعراض جانبية أخرى</strong></p><p dir="RTL"><strong>غير شائعة</strong> (قد تظهر لدى ما يصل إلى 1 من كل 100 شخص)</p><p dir="RTL"><u>علامات الحساسية:</u> قد تحدث تفاعلات تحسسية موضعية (ألم، احمرار، شرى، التهاب، كدمات، تورم وحكة) في موض الحقن. تختفي هذه الأعراض عادة بعد بضعة أسابيع من استخدام الأنسولين. إذا لم تختف، أو إذا انتشرت في جميع أنحاء جسمك، تحدث إلى طبيبك على الفور (انظر أيضًا &quot;ردود الفعل التحسسية الخطيرة&quot; أعلاه).</p><p dir="RTL"><u>مشاكل في الرؤية:</u> قد تتعرّض عند بدء استخدامك الأنسولين لاضطراب في الرؤيا، ولكن هذا الاضطراب عادة ما يكون مؤقتًا.</p><p dir="RTL"><u>التغييرات في موقع الحقن (الحثل الشحمي):</u> قد يتقلص النسيج الدهني الموجود تحت الجلد في موضع الحقن (ضمور شحمي) أو يثخن (تضخم شحمي). يؤدي تغيير موضع الحقن في كل جرعة حقن إلى تقليل خطر حدوث مثل هذه التغيرات الجلدية. إذا لاحظت وجود تنقير في جلدك أو سماكة في موضع الحقن، أخبر طبيبك أو ممرضتك. يمكن أن تتفاقم ردود الفعل هذه، أو قد تؤدي إلى تغير في امتصاص الأنسولين إذا قمت بالحقن في مثل هذا الموضع.</p><p dir="RTL"><u>تورم المفاصل:</u> قد يتسبب احتباس الماء عند البدء في استخدام الأنسولين في تورم حول الكاحلين والمفاصل الأخرى. يختفي هذا التورّم عادة بسرعة ولكن إذا لم يحدث ذلك تحدث إلى طبيبك.</p><p dir="RTL"><u>اعتلال الشبكية السكري</u> (مرض يصيب العين مرتبط بمرض السكري يمكن أن يؤدي إلى فقدان البصر): إذا كنت تعاني من اعتلال الشبكية السكري وتحسّن مستوى السكر في الدم بسرعة كبيرة، فقد يزداد اعتلال الشبكية سوءًا لديك. اسأل طبيبك عن هذا.</p><p dir="RTL"><strong>نادرة</strong> (قد تظهر لدى ما يصل إلى 1 من كل 1000 شخص)<br />&nbsp;</p><p dir="RTL"><u>الاعتلال العصبي المؤلم</u> (الألم الناتج عن تلف الأعصاب): إذا تحسّن مستوى السكر في الدم لديك بسرعة كبيرة، فقد تصاب بألم مرتبط بالأعصاب، وهذا ما يسمى الاعتلال العصبي المؤلم الحاد وعادة ما يكون عابرًا.</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong><br />إذا عانيت من أي أعراض جانبية، فتحدث إلى طبيبك أو ممرضتك أو الصيدلي. يتضمن ذلك أي أعراض جانبية محتملة غير مُدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الأعراض الجانبية مباشرةً عبر نظام الإبلاغ الوطني. يمكنك المساعدة في توفير مزيد من المعلومات حول سلامة هذا الدواء من خلال الإبلاغ عن الأعراض الجانبية.</p><p dir="RTL"><strong>الآثار المترتبة على مرض السكري</strong></p><p dir="RTL"><strong>ارتفاع مستوى سكر الدم (فرط السكر في الدم)</strong></p><p dir="RTL"><u>قد يحدث ارتفاع في مستوى السكر في الدم إذا:</u></p><p dir="RTL">&bull; لم تحقن كمية كافية من الأنسولين.</p><p dir="RTL">&bull; نسيت أن تحقن الأنسولين أو توقفت عن استخدامه.</p><p dir="RTL">&bull; كررت حقن الأنسولين بكمية أقل مما تحتاجه.</p><p dir="RTL">&bull; تعرّضت للعدوى و / أو الحمى.</p><p dir="RTL">&bull; أفرطت في تناول الطعام.</p><p dir="RTL">&bull; مارست التمارين الرياضية أقل من المعتاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>العلامات التحذيرية لارتفاع مستوى السكر في الدم:</u><br />&nbsp;</p><p dir="RTL">تظهر علامات التحذير تدريجياً. وتشمل: زيادة التبول؛ الشعور بالعطش؛ فقدان الشهية؛ الشعور بالغثيان (الغثيان أو القيء)؛ الشعور بالنعاس أو التعب؛ احمرار الوجه والعنق؛ جفاف الجلد؛ جفاف الفم وظهور رائحة الفاكهه (أسيتون) في النّفَس.<br />&nbsp;</p><p dir="RTL"><u>ماذا تفعل إذا كنت تعاني من ارتفاع مستوى السكر في الدم</u></p><p dir="RTL">&bull; إذا ظهرت عليك أي من العلامات المذكورة أعلاه: قم بفحص مستوى السكر في الدم لديك، واختبار<br />&nbsp; الكيتونات في البول إذا أمكن، ثم اطلب المشورة الطبية على الفور.</p><p dir="RTL">&bull; قد تكون هذه علامات على حالة خطيرة للغاية تسمى الحماض الكيتوني السكري (تراكم الحمض في الدم<br />&nbsp; لأن الجسم يُكسّر الدهون بدلاً من السكر). إذا لم تعالجها، فقد يؤدي ذلك إلى غيبوبة السكري والموت في<br />&nbsp; النهاية.</p><p dir="RTL"><strong>للإبلاغ عن أي أعراض جانبية</strong></p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL">المركز الوطني للتيقّظ والسلامة الدوائيّة (إن بّي سي)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال في الهيئة: 19999</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني:npc.drug@sfda.gov.sa</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني:https://ade.sfda.gov.sa/<br />&nbsp;</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دول الخليج الأخرى</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُرجى الاتصال بالجهات المُخوّلة المعنيّة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن أنظار ومتناول أيدي الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدوّن على الملصق والعلبة. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من نفس الشهر.</p><p dir="RTL">قبل الاستخدام الأول، قم بحفظ تروفيلوغ في الثلاجة (2 درجة مئوية - 8 درجات مئوية). لا تجمده. احتفظ بالقلم الجاهز في علبة الكرتون الخارجية لحمايته من الضوء.</p><p dir="RTL">ينبغي حفظ تروفيلوغ قلم الحقن مسبق التعبئة في درجة حرارة الغرفة (أقل من 30 درجة مئوية) لمدة أقصاها 4 أسابيع. لا تحتفظ بالقلم مسبق التعبئة الذي تستخدمه في الثلاجة. ينبغي عدم تخزين القلم مسبق التعبئة &nbsp;وهو موصول بالإبرة، بل ينبغي الحرص على وضع غطاء القلم عند عدم استخدامه لحمايته من الضوء.<br />&nbsp;</p><p dir="RTL">لا تستخدم قلم تروفيلوغ مسبق التعبئة إذا كان المحلول ملونًا أو يحتوي على جزيئات صلبة. يجب عليك استخدامه <strong>فقط</strong> إذا كان يشبه الماء. تحقق من هذا في كل مرة تقوم فيها بحقن نفسك.</p><p dir="RTL">لا تتخلص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ومن شأن هذه التدابير أن تساعد على حماية البيئة.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات تروفيلوغ</strong></p><p dir="RTL">&bull; المادة الفعالة هي الأنسولين أسبارت. يحتوي كل 1 مل من المحلول على 100 وحدة (ما يعادل<br />&nbsp; 3,5 مجم) من الأنسولين أسبارت. يحتوي كل قلم مسبق التعبئة (سولوستار) على 3 مل من محلول<br />&nbsp; الحقن، أي ما يعادل 300 وحدة من الأنسولين أسبارت. يُطلق كل قلم مسبق التعبئة (سولوستار) جرعات<br />&nbsp; تتراوح بين 1 إلى 80 وحدة في تدرجات مكوّنة من وحدة واحدة.</p><p dir="RTL">&bull; المكونات الأخرى هي: الفينول، ميتاكريسول، كلوريد الزنك، بولي سوربات 20، كلوريد الصوديوم، حمض<br />&nbsp; الهيدروكلوريك / هيدروكسيد الصوديوم والماء المُخصّص للحقن. قد يتم استخدام هيدروكسيد الصوديوم أو<br />&nbsp; حمض الهيدروكلوريك لضبط الحموضة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشكل الصيدلاني لتروفيلوغ ووصفه وحجم عبوته</strong><strong>.</strong></p><p dir="RTL">محلول تروفيلوغ للحقن هو محلول مائي صافٍ عديم اللون. كل قلم مسبق التعبئة من (سولوستار) يحتوي على 3 مل.</p><p dir="RTL">استخدم الإبر المتوافقة مع تروفيلوغ فقط (مثل الإبر من بي دي، يبسوميد، أرتسانا أو أوين مومفورد)</p><p dir="RTL">&nbsp;تتوفر أقلام تروفيلوغ مسبقة التعبئة (سولوستار) في علب تحتوي على 5 أقلام مُسبقة التعبئة.<br />قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك رخصة التسويق:</p><p dir="RTL">مجموعة سانوفي أفانتيس، 54، شارع لا بويتي، إف- 75008 باريس، فرنسا</p><p dir="RTL">المُصنّع:</p><p dir="RTL">سانوفي أفانتيس الألمانيّة جي إم بي إتش، دي-65926 فرانكفورت، ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            2020 ديسمبر
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Truvelog 100 units/ml solution for injection in pre-filled pen
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One ml solution contains 100 units (equivalent to 3.5 mg) insulin aspart*.
Truvelog 100 units/ml solution for injection in pre-filled pen
Each pre-filled pen contains 3 ml equivalent to 300 units insulin aspart. Each pre-filled pen delivers 1-80 units in steps of 1 unit.
* Truvelog is produced in Escherichia coli by recombinant DNA technology. For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection). Clear, colourless, aqueous solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Truvelog is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />The potency of insulin analogues, including insulin aspart, is expressed in units, whereas the potency of human insulin is expressed in international units.<br />Truvelog dosing is individual and determined in accordance with the needs of the patient. It should normally be used in combination with intermediate-acting or long-acting insulin.<br />Blood glucose monitoring and insulin dose adjustments are recommended to achieve optimal glycaemic control.<br />The individual insulin requirement in adults and children is usually between 0.5 and 1.0 unit/kg/day. In a basal-bolus treatment regimen 50%-70% of this requirement may be provided by Truvelog and the remainder by intermediate-acting or long-acting insulin.<br />Adjustment of dose may be necessary if patients undertake increased physical activity, change their usual diet or during concomitant illness.<br />Truvelog is only available as cartridge/pre-filled pen for subcutaneous use. Thus, it is not possible to use via intravenous route of administration. Other insulin aspart products offering such an option should be used.<br />Special populations Elderly<br />Truvelog can be used in elderly patients.<br />In elderly patients, glucose monitoring should be intensified and the insulin aspart dose adjusted on an individual basis.<br />Renal impairment<br />Renal impairment may reduce the patient&rsquo;s insulin requirements.<br />In patients with renal impairment, glucose monitoring should be intensified and the insulin aspart dose adjusted on an individual basis.<br />Hepatic impairment<br />Hepatic impairment may reduce the patient&rsquo;s insulin requirements.<br />In patients with hepatic impairment, glucose monitoring should be intensified and the insulin aspart dose adjusted on an individual basis.<br />Paediatric population<br />Truvelog can be used in adolescents and children aged 1 year and above in preference to soluble human insulin when a rapid onset of action might be beneficial, for example, in the timing of the injections in relation to meals (see sections 5.1 and 5.2).<br />The safety and efficacy of Truvelog in children below 1 year of age have not been established.<br />No data are available.<br />Transfer from other insulin medicinal products<br />When transferring from other insulin medicinal products, adjustment of the Truvelog dose and the dose of the basal insulin may be necessary. Truvelog has a faster onset and a shorter duration of action than soluble human insulin. When injected subcutaneously into the abdominal wall, the onset of action will occur within 10-20 minutes of injection. The maximum effect is exerted between 1 and 3 hours after the injection. The duration of action is 3 to 5 hours.<br />Close glucose monitoring is recommended during the transfer and in the initial weeks thereafter (see section 4.4).<br />Method of administration<br />Subcutaneous administration of Truvelog<br />Insulin aspart is a rapid-acting insulin analogue.<br />Truvelog is administered subcutaneously by injection in the upper arms, thighs, buttocks or abdomen. Injection sites should always be rotated within the same region in order to reduce the risk of lipodystrophy. Subcutaneous injection in the abdominal wall ensures a faster absorption than other injection sites. Compared to soluble human insulin the faster onset of action of insulin aspart is maintained regardless of the injection site. The duration of action will vary according to the dose, injection site, blood flow, temperature and level of physical activity.<br />Due to the faster onset of action, insulin aspart should generally be given immediately before a meal. When necessary insulin aspart can be given soon after a meal.<br />Truvelog 100 units/ml solution for injection in pre-filled pen<br />Truvelog 100 units/ml in pre-filled pen is only suitable for subcutaneous injections. If administration by syringe, intravenous injection or infusion pump is necessary, a vial should be used. Other insulin aspart products offering such an option should be used (see section 4.4). Truvelog in pre-filled pen delivers 1-80 units in increments of 1 unit.<br />Patients must visually verify the dialled units on the dose counter of the pen. Therefore, the requirement for patients to self-inject is that they can read the dose counter on the pen. Patients who are blind or have poor vision must be instructed to always get help/assistance from another person who has good vision and is trained in using the insulin device.<br />For detailed user instructions, please refer to the package leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Traceability<br />In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.<br />Travel<br />Before travelling between different time zones, the patient should seek the doctor&rsquo;s advice since this may mean that the patient has to take the insulin and meals at different times.<br />Hyperglycaemia<br />Inadequate dosing or discontinuation of treatment, especially in type 1 diabetes, may lead to hyperglycaemia and diabetic ketoacidosis. Usually the first symptoms of hyperglycaemia develop gradually over a period of hours or days. They include thirst, increased frequency of urination, nausea, vomiting, drowsiness, flushed dry skin, dry mouth, loss of appetite as well as acetone odour of breath. In type 1 diabetes, untreated hyperglycaemic events eventually lead to diabetic ketoacidosis, which is potentially lethal.<br />Hypoglycaemia<br />Omission of a meal or unplanned, strenuous physical exercise may lead to hypoglycaemia.<br />Especially in children, care should be taken to match insulin doses (especially in basal-bolus regimens) with food intake, physical activities and current blood glucose level in order to minimise the risk of hypoglycaemia.<br />Hypoglycaemia may occur if the insulin dose is too high in relation to the insulin requirement. In case of hypoglycaemia or if hypoglycaemia is suspected Truvelog must not be injected. After stabilisation of patient&rsquo;s blood glucose adjustment of the dose should be considered (see sections 4.8 and 4.9).<br />Patients whose blood glucose control is greatly improved, e.g. by intensified insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia, and should be advised accordingly. Usual warning symptoms may disappear in patients with longstanding diabetes.<br />A consequence of the pharmacodynamics of rapid-acting insulin analogues is that if hypoglycaemia occurs, it may occur earlier after an injection when compared with soluble human insulin.<br />Since Truvelog should be administered in immediate relation to a meal, the rapid onset of action should be considered in patients with concomitant diseases or treatment where a delayed absorption<br />of food might be expected.<br />Concomitant illness, especially infections and feverish conditions, usually increases the patient&rsquo;s insulin requirements. Concomitant diseases in the kidney, liver or affecting the adrenal, pituitary or thyroid gland can require changes in the insulin dose.<br />When patients are transferred between different types of insulin medicinal products, the early warning symptoms of hypoglycaemia may change or become less pronounced than those experienced with their previous insulin.<br />Transfer from other insulin medicinal products<br />Transferring a patient to another type or brand of insulin should be done under strict medical supervision. Changes in strength, brand (manufacturer), type, origin (animal, human insulin or human insulin analogue) and/or method of manufacture (recombinant DNA versus animal source insulin) may result in the need for a change in dose. Patients transferred to Truvelog from another type of insulin may require an increased number of daily injections or a change in dose from that used with their usual insulin medicinal products. If an adjustment is needed, it may occur with the first dose or during the first few weeks or months.<br />Injection site reactions<br />As with any insulin therapy, injection site reactions may occur and include pain, redness, hives, inflammation, bruising, swelling and itching. Continuous rotation of the injection site within a given area reduces the risk of developing these reactions. Reactions usually resolve in a few days to a few weeks. On rare occasions, injection site reactions may require discontinuation of insulin aspart.<br />Combination of Truvelog with pioglitazone<br />Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. This should be kept in mind if treatment with the combination of pioglitazone and Truvelog is considered. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs.<br />Avoidance of accidental mix-ups/medication errors<br />Patients must be instructed to always check the insulin label before each injection to avoid accidental mix-ups between Truvelog and other insulin products.<br />Handling of the SoloStar pre-filled pen<br />Truvelog 100 units/ml in pre-filled pen is only suitable for subcutaneous injections. If administration by syringe, intravenous injection or infusion pump is necessary, a vial should be used. Other insulin aspart products offering such an option should be used (see section 4.2).<br />Insulin antibodies<br />Insulin administration may cause insulin antibodies to form. In rare cases, the presence of such insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency to hyper- or hypoglycaemia.<br />Excipients<br />This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e., essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A number of medicinal products are known to interact with the glucose metabolism. The following substances may reduce the patient&#39;s insulin requirements:<br />Oral antidiabetic medicinal products, monoamine oxidase inhibitors (MAOI), beta-blockers, angiotensin converting enzyme (ACE) inhibitors, salicylates, anabolic steroids and sulphonamides.<br />The following substances may increase the patient&rsquo;s insulin requirements:<br />Oral contraceptives, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth hormone and danazol.<br />Beta-blockers may mask the symptoms of hypoglycaemia. Octreotide/lanreotide may either increase or decrease the insulin requirement. Alcohol may intensify or reduce the hypoglycaemic effect of insulin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Truvelog (insulin aspart) can be used in pregnancy. Data from two randomised controlled clinical trials (322 and 27 exposed pregnancies) do not indicate any adverse effect of insulin aspart on pregnancy or on the health of the foetus/newborn when compared to human insulin (see section 5.1).<br />Intensified blood glucose control and monitoring of pregnant women with diabetes (type 1 diabetes, type 2 diabetes or gestational diabetes) are recommended throughout pregnancy and when contemplating pregnancy. Insulin requirements usually fall in the first trimester and increase subsequently during the second and third trimester. After delivery, insulin requirements normally return rapidly to pre-pregnancy values.<br />Breast-feeding<br />There are no restrictions on treatment with Truvelog during breast-feeding. Insulin treatment of the nursing mother presents no risk to the baby. However, the Truvelog dose may need to be adjusted.<br />Fertility<br />Animal reproduction studies have not revealed any differences between insulin aspart and human insulin regarding fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The patient&rsquo;s ability to concentrate and react may be impaired as a result of hypoglycaemia. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or using machines).<br />Patients should be advised to take precautions to avoid hypoglycaemia while driving, this is particularly important in those who have reduced or absent awareness of the warning signs of hypoglycaemia or have frequent episodes of hypoglycaemia. The advisability of driving should be considered in these circumstances.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />Adverse reactions observed in patients using Truvelog are mainly due to the pharmacologic effect of insulin.<br />The most frequently reported adverse reaction during treatment is hypoglycaemia. The frequencies of hypoglycaemia vary with patient population, dose regimens and level of glycaemic control (see section 4.8 Description of selected adverse reactions).<br />At the beginning of the insulin treatment, refraction anomalies, oedema and injection site reactions (pain, redness, hives, inflammation, bruising, swelling and itching at the injection site) may occur. These reactions are usually of transitory nature. Fast improvement in blood glucose control may be associated with acute painful neuropathy, which is usually reversible. Intensification of insulin therapy with abrupt improvement in glycaemic control may be associated with temporary worsening of diabetic retinopathy, while long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy.<br />Tabulated list of adverse reactions<br />Adverse reactions listed below are based on clinical trial data and classified according to System Organ Class. Frequency categories are defined according to the following convention: Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data).<br /><img src="data:image/png;base64,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" alt="" width="715" height="400" vspace="0" hspace="0" border="0" style="width:715px;height:400px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /><br />*See section 4.8 Description of selected adverse reactions Description of selected adverse reactions<br />Anaphylactic reactions<br />The occurrence of generalised hypersensitivity reactions (including generalised skin rash, itching, sweating, gastrointestinal upset, angioneurotic oedema, difficulties in breathing, palpitation and reduction in blood pressure) is very rare but can potentially be life threatening.<br />Hypoglycaemia<br />The most frequently reported adverse reaction is hypoglycaemia. It may occur if the insulin dose is too<br />high in relation to the insulin requirement. Severe hypoglycaemia may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or even death.<br />The symptoms of hypoglycaemia usually occur suddenly. They may include cold sweats, cool pale skin, fatigue, nervousness or tremor, anxiousness, unusual tiredness or weakness, confusion, difficulty in concentration, drowsiness, excessive hunger, vision changes, headache, nausea and palpitation.<br />In clinical trials, the frequency of hypoglycaemia varied with patient population, dose regimens and level of glycaemic control. During clinical trials the overall rates of hypoglycaemia did not differ between patients treated with insulin aspart compared to human insulin.<br />Lipodystrophy<br />Lipodystrophy (including lipohypertrophy, lipoatrophy) may occur at the injection site. Continuous rotation of the injection site within the particular injection area reduces the risk of developing these reactions.<br />Paediatric population<br />Based on post-marketing sources and clinical trials with insulin aspart, the frequency, type and severity of adverse reactions observed in the paediatric population do not indicate any differences to the broader experience in the general population.<br />Other special populations<br />Based on post-marketing sources and clinical trials with insulin aspart, the frequency, type and severity of adverse reactions observed in the elderly patients and in patients with renal or hepatic impairment do not indicate any differences to the broader experience in the general population.<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.<br />To reports any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance Centre (NPC):<br />&bull; SFDA Call Center: 19999<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: https://ade.sfda.gov.sa/<br />&bull; Other GCC States:<br />Please contact the relevant competent authority<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A specific overdose for insulin cannot be defined, however, hypoglycaemia may develop over sequential stages if too high doses relative to the patient&rsquo;s requirement are administered:<br />&bull; Mild hypoglycaemic episodes can be treated by oral administration of glucose or sugary products. It is therefore recommended that the diabetic patient always carries sugar-containing products.<br />&bull; Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated with glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously by a trained person, or with glucose given intravenously by physicians or other healthcare staff. Glucose must be given intravenously, if the patient does not respond to glucagon within 10 to 15 minutes. Upon regaining consciousness, administration of oral carbohydrates is recommended for the patient in order to prevent a relapse.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs used in diabetes. Insulins and analogues for injection, fast-acting. ATC code: A10AB05<br />Truvelog is a biosimilar medicinal product.<br />Mechanism of action and pharmacodynamic effects<br />The blood glucose lowering effect of insulin aspart is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.<br />Insulin aspart produces a more rapid onset of action compared to soluble human insulin, together with a lower glucose concentration, as assessed within the first four hours after a meal. Insulin aspart has a shorter duration of action compared to soluble human insulin after subcutaneous injection.<br /><img src="data:image/png;base64,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" alt="" width="451" height="313" vspace="0" hspace="0" border="0" style="width:451px;height:313px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /><br />Fig. I. Blood glucose concentrations following a single pre-meal dose of insulin aspart injected immediately before a meal (solid curve) or soluble human insulin administered 30 minutes before a meal (hatched curve) in patients with type 1 diabetes mellitus.<br />When insulin aspart is injected subcutaneously, the onset of action will occur within 10 to 20 minutes of injection. The maximum effect is exerted between 1 and 3 hours after injection. The duration of action is 3 to 5 hours.<br />Clinical efficacy<br />Clinical trials in patients with type 1 diabetes have demonstrated a lower postprandial blood glucose with insulin aspart compared to soluble human insulin (Fig. I). In two long-term open label trials in patients with type 1 diabetes comprising 1070 and 884 patients, respectively, insulin aspart reduced glycated haemoglobin by 0.12 [95% C.I. 0.03; 0.22] percentage points and by 0.15 [95% C.I. 0.05; 0.26] percentage points compared to human insulin; a difference of limited clinical significance.<br />Clinical trials in patients with type 1 diabetes have demonstrated a reduced risk of nocturnal hypoglycaemia with insulin aspart compared with soluble human insulin. The risk of daytime hypoglycaemia was not significantly increased.<br />Insulin aspart is equipotent to soluble human insulin on a molar basis. Special populations<br />Elderly<br />A randomised, double-blind cross-over PK/PD trial comparing insulin aspart with soluble human insulin was performed in elderly patients with type 2 diabetes (19 patients aged 65-83 years, mean age<br />70 years). The relative differences in the pharmacodynamic properties (GIRmax,AUCGIR, 0-120 min) between insulin aspart and human insulin in the elderly were similar to those seen in healthy subjects and in younger patients with diabetes.<br />Paediatric population<br />A clinical trial comparing preprandial soluble human insulin with postprandial insulin aspart was performed in small children (20 patients aged 2 to less than 6 years, studied for 12 weeks, among those four were younger than 4 years old) and a single dose PK/PD trial was performed in children (6- 12 years) and adolescents (13-17 years). The pharmacodynamic profile of insulin aspart in children was similar to that seen in adults.<br />The efficacy and safety of insulin aspart given as bolus insulin in combination with either insulin detemir or insulin degludec as basal insulin has been studied for up to 12 months, in two randomised controlled clinical trials in adolescents and children aged 1 to less than 18 years (n=712). The trials included 167 children aged 1-5 years, 260 aged 6-11 and 285 aged 12-17. The observed improvements in HbA1c and the safety profiles were comparable between all age groups.<br />Pregnancy<br />A clinical trial comparing safety and efficacy of insulin aspart vs. human insulin in the treatment of pregnant women with type 1 diabetes (322 exposed pregnancies (insulin aspart: 157; human insulin: 165) did not indicate any adverse effect of insulin aspart on pregnancy or on the health of the foetus/newborn.<br />In addition the data from a clinical trial including 27 women with gestational diabetes randomised to treatment with insulin aspart vs. human insulin (insulin aspart: 14; human insulin: 13) showed similar safety profiles between treatments.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption, distribution and elimination<br />In insulin aspart substitution of amino acid proline with aspartic acid at position B28 reduces the tendency to form hexamers as observed with soluble human insulin. Insulin aspart is therefore more rapidly absorbed from the subcutaneous layer compared to soluble human insulin.<br />The time to maximum concentration is, on average, half of that for soluble human insulin. A mean maximum plasma concentration of 492&plusmn;256 pmol/L was reached 40 (interquartile range: 30&ndash;40) minutes after a subcutaneous dose of 0.15 unit/kg bodyweight in type 1 diabetic patients. The insulin concentrations returned to baseline about 4 to 6 hours after dose. The absorption rate was somewhat slower in type 2 diabetic patients, resulting in a lower Cmax (352&plusmn;240 pmol/L) and later tmax (60 (interquartile range: 50&ndash;90) minutes). The intra-individual variability in time to maximum concentration is significantly less for insulin aspart than for soluble human insulin, whereas the intra-individual variability in Cmax for insulin aspart is larger.<br />Special populations<br />Elderly<br />The relative differences in pharmacokinetic properties between insulin aspart and soluble human insulin in elderly patients (65-83 years, mean age 70 years) with type 2 diabetes were similar to those observed in healthy subjects and in younger patients with diabetes. A decreased absorption rate was observed in elderly patients, resulting in a later tmax (82 (interquartile range: 60-120) minutes), whereas Cmax was similar to that observed in younger patients with type 2 diabetes and slightly lower than in patients with type 1 diabetes.<br />Hepatic impairment<br />A single dose pharmacokinetic study of insulin aspart was performed in 24 subjects with hepatic function ranging from normal to severely impaired. In patients with hepatic impairment, absorption rate was decreased and more variable, resulting in delayed tmax from about 50 min in subjects with normal hepatic function to about 85 min in patients with moderate and severe hepatic impairment. AUC, Cmax and CL/F were similar in patients with reduced hepatic function compared with subjects with normal hepatic function.<br />Renal impairment<br />A single dose pharmacokinetic study of insulin aspart in 18 subjects with renal function ranging from normal to severely impaired was performed. No apparent effect of creatinine clearance values on AUC, Cmax, CL/F and tmax of insulin aspart was found. Data were limited in patients with moderate and severe renal impairment. Patients with renal failure necessitating dialysis treatment were not investigated.<br />Paediatric population<br />The pharmacokinetic and pharmacodynamic properties of insulin aspart were investigated in children (6&ndash;12 years) and adolescents (13&ndash;17 years) with type 1 diabetes. Insulin aspart was rapidly absorbed in both age groups, with similar tmax as in adults. However, Cmax differed between the age groups, stressing the importance of the individual titration of insulin aspart.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and toxicity to reproduction and development.<br />In in vitro tests, including binding to insulin and IGF-1 receptor sites and effects on cell growth, insulin aspart behaved in a manner that closely resembled human insulin. Studies also demonstrate that the dissociation of binding to the insulin receptor of insulin aspart is equivalent to human insulin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Phenol 1.5 mg<br />Metacresol 1.72 mg<br />Zinc chloride 0.04 mg<br />Polysorbate 20 0.02 mg<br />Sodium chloride 6.80 mg<br />Hydrochloric acid (for pH adjustment) q.s. pH 7.4<br />Sodium hydroxide (for pH adjustment) q.s. pH 7.4<br />Water for injections q.s. 1 mL<br />Per 1 mL</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be diluted or mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Before first use: 30 months.
After first use: 4 weeks.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Truvelog 100 units/ml solution for injection in pre-filled pen<br />Before first use<br />Store in a refrigerator (2&deg;C - 8&deg;C). Do not freeze.<br />Keep the pre-filled pen in the outer carton in order to protect from light.<br />After first use<br />Store below 30&deg;C. Do not refrigerate. Do not freeze. Keep the pen cap on the pen in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Truvelog 100 units/ml solution for injection in pre-filled pen<br />Type 1 colourless glass cartridge with a grey plunger (bromobutyl rubber) and a flanged cap (aluminium) with a sealing disk (laminate of isoprene and bromobutyl rubber) sealed in a disposable pen injector (SoloStar).<br />Each pre-filled pen contains 3 ml of solution. Pack sizes: 5 pre-filled pens.<br />Not all pack sizes may be marketed. Needles are not included in the pack.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Inspect the Truvelog solution. Do not use this medicinal product if you notice that the solution is not clear, colourless and aqueous.<br />Any unused medicinal product or waste material should be disposed of in accordance with local requirements.<br />Truvelog 100 units/ml solution for injection in pre-filled pen<br />To prevent the possible transmission of disease, each pen must be used by one patient only, even if the needle is changed.<br />The pre-filled pen should not be stored with the needle attached. Always use a new needle for each injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                sanofi-aventis groupe 54, rue La Boétie
F - 75008 Paris France
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dec 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>